KR20200110820A - 베타-클로로시클로펜탄의 친수성 에스테르 전구약물의 이용에 의한 감소된 중심 각막 비후 - Google Patents
베타-클로로시클로펜탄의 친수성 에스테르 전구약물의 이용에 의한 감소된 중심 각막 비후 Download PDFInfo
- Publication number
- KR20200110820A KR20200110820A KR1020207026858A KR20207026858A KR20200110820A KR 20200110820 A KR20200110820 A KR 20200110820A KR 1020207026858 A KR1020207026858 A KR 1020207026858A KR 20207026858 A KR20207026858 A KR 20207026858A KR 20200110820 A KR20200110820 A KR 20200110820A
- Authority
- KR
- South Korea
- Prior art keywords
- unsubstituted
- substituted
- compound
- alkyl
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261693437P | 2012-08-27 | 2012-08-27 | |
| US61/693,437 | 2012-08-27 | ||
| PCT/US2013/056418 WO2014035827A1 (en) | 2012-08-27 | 2013-08-23 | Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157007444A Division KR102304111B1 (ko) | 2012-08-27 | 2013-08-23 | 베타-클로로시클로펜탄의 친수성 에스테르 전구약물의 이용에 의한 감소된 중심 각막 비후 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200110820A true KR20200110820A (ko) | 2020-09-25 |
Family
ID=49117974
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207026858A Ceased KR20200110820A (ko) | 2012-08-27 | 2013-08-23 | 베타-클로로시클로펜탄의 친수성 에스테르 전구약물의 이용에 의한 감소된 중심 각막 비후 |
| KR1020157007444A Expired - Fee Related KR102304111B1 (ko) | 2012-08-27 | 2013-08-23 | 베타-클로로시클로펜탄의 친수성 에스테르 전구약물의 이용에 의한 감소된 중심 각막 비후 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157007444A Expired - Fee Related KR102304111B1 (ko) | 2012-08-27 | 2013-08-23 | 베타-클로로시클로펜탄의 친수성 에스테르 전구약물의 이용에 의한 감소된 중심 각막 비후 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9024042B2 (https=) |
| EP (1) | EP2888239B1 (https=) |
| JP (1) | JP6270848B2 (https=) |
| KR (2) | KR20200110820A (https=) |
| CN (1) | CN104684904B (https=) |
| AU (1) | AU2013309124B2 (https=) |
| CA (1) | CA2882743C (https=) |
| DK (1) | DK2888239T3 (https=) |
| ES (1) | ES2711425T3 (https=) |
| TR (1) | TR201900863T4 (https=) |
| WO (1) | WO2014035827A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2711425T3 (es) | 2012-08-27 | 2019-05-03 | Allergan Inc | Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos |
| JP6626831B2 (ja) * | 2014-02-20 | 2019-12-25 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中心肥厚の減少 |
| WO2015175544A1 (en) * | 2014-05-12 | 2015-11-19 | Allergan, Inc. | Quaternary ammonium alkyl esters of prostanoid derivatives as stable prodrugs |
| WO2015179815A1 (en) * | 2014-05-22 | 2015-11-26 | Allergan, Inc. | Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use |
| ES2757798T3 (es) * | 2014-10-02 | 2020-04-30 | Allergan Inc | Profármacos de éster de gamma-lactamas y su uso |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6353000B1 (en) * | 1996-11-12 | 2002-03-05 | Alcon Laboratories, Inc. | 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension |
| DE10322843A1 (de) | 2003-05-19 | 2004-12-16 | Clariant Gmbh | Verfahren zur Herstellung von Anilinboronsäuren und ihren Derivaten |
| EP1812017A2 (en) * | 2004-10-21 | 2007-08-01 | Duke University | Ophthamological drugs |
| US7091231B2 (en) * | 2004-12-10 | 2006-08-15 | Allergan, Inc. | 12-Aryl prostaglandin analogs |
| US20070254920A1 (en) | 2006-04-26 | 2007-11-01 | Aerie Pharmaceuticals, Inc. | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use |
| ES2549863T3 (es) * | 2006-07-11 | 2015-11-02 | Allergan, Inc. | Derivados de ciclopentano como agentes antiglaucoma |
| US7947732B2 (en) * | 2007-07-13 | 2011-05-24 | Allergan, Inc. | Therapeutic substituted chlorocyclopentanols |
| US7732443B2 (en) * | 2008-03-18 | 2010-06-08 | Yariv Donde | Therapeutic substituted cyclopentanes |
| US7737140B2 (en) * | 2008-04-24 | 2010-06-15 | Allergan, Inc. | Therapeutic compounds |
| EP2291346A2 (en) * | 2008-05-15 | 2011-03-09 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
| DK2498783T3 (en) | 2009-11-09 | 2018-12-10 | Allergan Inc | COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH |
| US20110136872A1 (en) | 2009-12-09 | 2011-06-09 | Burk Robert M | Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof |
| ES2711425T3 (es) | 2012-08-27 | 2019-05-03 | Allergan Inc | Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos |
| US9090595B2 (en) | 2012-08-27 | 2015-07-28 | Allergan, Inc. | Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes |
-
2013
- 2013-08-23 ES ES13759081T patent/ES2711425T3/es active Active
- 2013-08-23 KR KR1020207026858A patent/KR20200110820A/ko not_active Ceased
- 2013-08-23 AU AU2013309124A patent/AU2013309124B2/en not_active Ceased
- 2013-08-23 EP EP13759081.6A patent/EP2888239B1/en active Active
- 2013-08-23 CA CA2882743A patent/CA2882743C/en active Active
- 2013-08-23 US US13/974,975 patent/US9024042B2/en active Active
- 2013-08-23 DK DK13759081.6T patent/DK2888239T3/en active
- 2013-08-23 WO PCT/US2013/056418 patent/WO2014035827A1/en not_active Ceased
- 2013-08-23 JP JP2015529881A patent/JP6270848B2/ja not_active Expired - Fee Related
- 2013-08-23 KR KR1020157007444A patent/KR102304111B1/ko not_active Expired - Fee Related
- 2013-08-23 CN CN201380051147.7A patent/CN104684904B/zh not_active Expired - Fee Related
- 2013-08-23 TR TR2019/00863T patent/TR201900863T4/tr unknown
-
2015
- 2015-04-13 US US14/685,414 patent/US9427401B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102304111B1 (ko) | 2021-09-23 |
| TR201900863T4 (tr) | 2019-02-21 |
| EP2888239A1 (en) | 2015-07-01 |
| US20140057975A1 (en) | 2014-02-27 |
| KR20150046269A (ko) | 2015-04-29 |
| ES2711425T3 (es) | 2019-05-03 |
| AU2013309124B2 (en) | 2018-03-01 |
| CA2882743A1 (en) | 2014-03-06 |
| AU2013309124A1 (en) | 2015-03-12 |
| EP2888239B1 (en) | 2018-11-28 |
| CN104684904B (zh) | 2017-10-13 |
| HK1211031A1 (en) | 2016-05-13 |
| CA2882743C (en) | 2021-11-30 |
| JP2015528463A (ja) | 2015-09-28 |
| US9427401B2 (en) | 2016-08-30 |
| WO2014035827A1 (en) | 2014-03-06 |
| CN104684904A (zh) | 2015-06-03 |
| US20150322036A1 (en) | 2015-11-12 |
| US9024042B2 (en) | 2015-05-05 |
| JP6270848B2 (ja) | 2018-01-31 |
| DK2888239T3 (en) | 2019-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102304111B1 (ko) | 베타-클로로시클로펜탄의 친수성 에스테르 전구약물의 이용에 의한 감소된 중심 각막 비후 | |
| AU2015259752B2 (en) | Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes | |
| US9090595B2 (en) | Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes | |
| JP6662864B2 (ja) | ガンマ−ラクタムのエステルプロドラッグ及びそれらの使用 | |
| HK1211031B (en) | Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes | |
| HK1229812A1 (en) | Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes | |
| HK40041854A (en) | Ester prodrugs of gamma-lactams and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20200917 Application number text: 1020157007444 Filing date: 20150324 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20201016 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20210128 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20211117 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20210128 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |